Directed differentiation of embryonic stem cells and uses thereof

• US 20060194321A1
• Filed: 01/30/2006
• Published: 08/31/2006
• Est. Priority Date: 01/31/2005
• Status: Abandoned Application

• Current Assignee: ES Cell International Pte Ltd. (Lineage Cell Therapeutics, Inc.)
• Original Assignee: ES Cell International Pte Ltd. (Lineage Cell Therapeutics, Inc.)
• Inventors: Dunn, Norris Ray, Sun, William, Colman, Alan, Rust, William Lathrop, Phillips, Blaine, Martin, Hentze Hannes
• Application Number:
  US11/342,957
• Publication Number:
  US 20060194321A1
• Time in Patent Office: Days
• US Class Current: 435/377
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/119 Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
• CPC Class Codes: C12N 2501/12 Hepatocyte growth factor [HGF]
• CPC Class Codes: C12N 2501/148 Transforming growth factor alpha [TGF-a]
• CPC Class Codes: C12N 2501/15 Transforming growth factor beta (TGF-β)
• CPC Class Codes: C12N 2501/155 Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0676 Pancreatic cells

Abstract

The present invention provides methods for the directed differentiation of embryonic stem cells along the endodermal lineage, especially the pancreatic lineage.

Claims

1. A method for directed differentiation of embryonic stem (ES) cells into pancreatic lineage, comprising:

contacting the ES cells for a sufficient period of time with a sufficient amount of one or more early factors (EFs) selected from activin A, BMP2, BMP4, or nodal, wherein the pancreatic lineage cells express pancreatic lineage marker(s), and/or exhibit a pancreatic lineage function.

2. The method of claim 1, wherein the pancreatic lineage cells express Pdx-1 and/or insulin, and/or are responsive to glucose, and/or secret C-peptide.

3. The method of claim 2, wherein the pancreatic lineage cells are Insulin-producing cells.

4. The method of claim 1, wherein the ES cells are cultured as embryoid bodies (EBs), plated directly onto a support matrix, and/or plated directly onto tissue culture plates.

5. The method of claim 4, wherein the EBs are cultured in a floating suspension culture, in a support matrix, and/or on a filter.

6. The method of claim 4, wherein the EBs are cultured in a support matrix only during the period when the EBs are in contact with the EFs.

7. The method of claim 4, wherein the support matrix is MATRIGEL™

.

8. The method of claim 4, wherein the EBs are generated from ES cells grown on MEF (mouse embryonic feeder) or other feeder layers, or from ES cells grown under feeder-free conditions.

9. The method of claim 1, wherein the ES cells are human ES cells.

10. The method of claim 1, wherein the ES cells are mouse ES cells.

11. The method of claim 1, wherein the ES cells are partially or terminally differentiated into the pancreatic lineage.

12. The method of claim 1, wherein the ES cells are contacted with the EFs for about 15 days.

13. The method of claim 1, wherein the EFs comprise activin A and BMP4.

14. The method of claim 1, wherein the EFs comprise about 50 ng/mL of activin A and about 50 ng/mL of BMP4.

15. The method of claim 1, further comprising contacting the ES cells, subsequent to contacting the ES cells with the EFs, with a sufficient amount of one or more late factors (LFs) for a second sufficient period of time.

16. The method of claim 15, wherein the one or more LFs are HGF, exendin4, betacellulin, and nicotinamide.

17. The method of claim 15, wherein the one or more LFs include about 50 ng/mL of HGF, about 10 ng/mL of exendin4, and about 50 ng/mL of β

-cellulin.

18. The method of claim 15, wherein the ES cells are contacted with the EFs for about 10 days, and are subsequently contacted with the LFs for about 10 days.

19. The method of claim 18, wherein the EFs comprise about 50 ng/mL of activin A and about 50 ng/mL of BMP4, and the LFs include about 50 ng/mL of HGF, about 10 ng/mL of exendin4, and about 50 ng/mL of β

-cellulin.

20. The method of claim 15, further comprising contacting the ES cells, subsequent to the initiation protocol and during a maturation protocol, consecutively with:

(1) a basal medium for about 6 days;

(2) about 20 ng/ml FGF-18, and about 2 μ

g/ml Heparin in the basal medium for about 5-6 days;

(3) about 20 ng/ml FGF-18, about 2 μ

g/ml Heparin, about 10 ng/ml EGF, about 4 ng/ml TGFα

, about 30 ng/ml IGF1, about 30 ng/ml IGF2, and about 10 ng/ml VEGF in the basal medium for about 4-5 days;

(4) about 10 μ

M Forskolin, about 40 ng/ml HGF, and about 200 ng/ml PYY for about 3-4 days; and

,

(5) about 100 ng/ml Exendin-4, and about 5 mM Nicotinamide for about 3-4 days.

21. The method of claim 20, wherein the ES cells are not dissociated by dispase between step (1) and (2).

22. The method of claim 20, wherein FBS (if any) in the medium is replaced with a chemically defined serum replacer (SR).

23. The method of claim 15, further comprising contacting the ES cells, subsequent to the EF and LF treatment, and during a maturation protocol, with about 10 μ

M Forskolin, about 40 ng/ml HGF, and about 200 ng/ml PYY for about 3-4 days.

24. The method of claim 23, wherein the ES cells are grown on fibronectin-coated tissue culture surfaces during the maturation protocol.

25. The method of claim 23, wherein the differentiated cells release C-peptide and/or are responsive to glucose stimulation.

26. The method of claim 23, wherein FBS (if any) in the medium is replaced with a chemically defined serum replacer (SR).

27. The method of claim 1, further comprising contacting the ES cells, subsequent to contacting the ES cells with the EFs and during a maturation protocol, consecutively with:

(1) about 20 ng/ml FGF-18, and about 2 μ

g/ml Heparin in a basal medium for about 8 days;

(2) about 20 ng/ml FGF-18, about 2 μ

g/ml Heparin, about 10 ng/ml EGF, about 4 ng/ml TGFα

, about 30 ng/ml IGF1, about 30 ng/ml IGF2, and about 10 ng/ml VEGF in the basal medium for about 6 days; and

(3) about 10 μ

M Forskolin, about 40 ng/ml HGF, and about 200 ng/ml PYY for about 5 days.

28. The method of claim 27, wherein the differentiated cells release C-peptide.

29. The method of claim 27, wherein step (1) lasts 6 days, steps (2) and (3) last 4 days each.

30. Differentiated pancreatic lineage cells or cell cultures obtained through the method of claim 1.

31. Differentiated pancreatic lineage cells or cell cultures obtained through the method of claim 2.

32. The differentiated pancreatic lineage cells or cell cultures of claim 31, which are partially differentiated.

33. The differentiated pancreatic lineage cells or cell cultures of claim 31, which are terminally differentiated.

34. The differentiated pancreatic lineage cells or cell cultures of claim 31, which mimic the function, in whole or in part, of Insulin-producing cells.

35. Differentiated pancreatic lineage cells or cell cultures obtained through the method of claim 15.

36. Differentiated pancreatic lineage cells or cell cultures obtained through the method of claim 20.

37. Differentiated pancreatic lineage cells or cell cultures obtained through the method of claim 23.

38. Differentiated pancreatic lineage cells or cell cultures obtained through the method of claim 27.

39. A method for the treatment or prophylaxis, in an individual, of diseases, injuries, or conditions of the pancreas characterized by impaired pancreatic function, comprising administering to the individual the differentiated pancreatic lineage cells of claim 30.

40. The method of claim 39, wherein the impaired pancreatic function includes impaired ability to properly regulate glucose metabolism in an affected individual.

41. The method of claim 39, wherein the condition is type I or type II diabetes.

42. The method of claim 39, which is in conjunction with one or more additional therapies effective for the treatment or prophylaxis of the diseases, injuries, or conditions.